- Home
- CSQ vs TVTX Comparison
CSQ vs TVTX Comparison
Compare CSQ & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSQ
- TVTX
- Stock Information
- Founded
- CSQ 2003
- TVTX 2008
- Country
- CSQ United States
- TVTX United States
- Employees
- CSQ N/A
- TVTX N/A
- Industry
- CSQ Finance Companies
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- CSQ Finance
- TVTX Health Care
- Exchange
- CSQ Nasdaq
- TVTX Nasdaq
- Market Cap
- CSQ 3.1B
- TVTX 2.5B
- IPO Year
- CSQ N/A
- TVTX N/A
- Fundamental
- Price
- CSQ $19.30
- TVTX $35.16
- Analyst Decision
- CSQ
- TVTX Strong Buy
- Analyst Count
- CSQ 0
- TVTX 16
- Target Price
- CSQ N/A
- TVTX $35.20
- AVG Volume (30 Days)
- CSQ 220.3K
- TVTX 2.0M
- Earning Date
- CSQ 01-01-0001
- TVTX 10-30-2025
- Dividend Yield
- CSQ 7.53%
- TVTX N/A
- EPS Growth
- CSQ N/A
- TVTX N/A
- EPS
- CSQ N/A
- TVTX N/A
- Revenue
- CSQ N/A
- TVTX $435,826,000.00
- Revenue This Year
- CSQ N/A
- TVTX $83.23
- Revenue Next Year
- CSQ N/A
- TVTX $41.49
- P/E Ratio
- CSQ N/A
- TVTX N/A
- Revenue Growth
- CSQ N/A
- TVTX 114.22
- 52 Week Low
- CSQ $12.50
- TVTX $12.91
- 52 Week High
- CSQ $16.45
- TVTX $35.34
- Technical
- Relative Strength Index (RSI)
- CSQ 55.86
- TVTX 85.39
- Support Level
- CSQ $19.14
- TVTX $26.79
- Resistance Level
- CSQ $19.47
- TVTX $30.97
- Average True Range (ATR)
- CSQ 0.23
- TVTX 1.22
- MACD
- CSQ 0.01
- TVTX 0.38
- Stochastic Oscillator
- CSQ 75.71
- TVTX 98.15
About CSQ Calamos Strategic Total Return
Calamos Strategic Total Return Fund is a diversified, closed-end management investment company. The fund's objective is to provide total return through a combination of capital appreciation and current income. Its investment portfolio comprises equities, convertible securities, and high-yield corporate bonds.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.